

The Post-Septic Peripheral Myeloid Compartment Reveals Unexpected Diversity in Myeloid-Derived Suppressor Cells

Evan L. Barrios^{1†}, John Leary^{2†}, Dijolia B. Darden¹, Jaimar C. Rincon¹, Micah Willis¹, Valerie E. Polcz¹, Gwendolyn S. Gillies¹, Jennifer A. Munley¹, Marvin L. Dirain¹, Ricardo Ungaro¹, Dina C. Nacionales¹, Marie-Pierre L. Gauthier³, Shawn D. Larson¹, Laurence Morel⁴, Tyler J. Loftus¹, Alicia M. Mohr¹, Robert Maile¹, Michael P. Kladde³, Clayton E. Mathews⁵, Maigan A. Brusko⁵, Todd M. Brusko⁵, Lyle L. Moldawer¹, Rhonda Bacher^{2*}, Philip A. Efron^{1*}

¹Sepsis and Critical Illness Research Center, Department of Surgery, University of Florida College of Medicine; Gainesville, Florida, USA

²Department of Biostatistics, University of Florida College of Medicine and Public Health and Health Sciences, Gainesville, Florida, USA

³Department of Biochemistry and Molecular Biology, University of Florida College of Medicine, Gainesville, Florida, USA

⁴Department of Microbiology and Immunology, University of Texas San Antonio School of Medicine; San Antonio, Texas, USA

⁵Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine; Gainesville, Florida, USA

Footnotes:

†These authors contributed equally to the work and share first authorship.

*These authors are both corresponding authors.

*Correspondence:

Philip A. Efron, M.D.

Department of Surgery, University of Florida College of Medicine

Room 6116, Shands Hospital

1600 SW Archer Road

Gainesville, Florida 32610-0019

ORCID: 0000-0002-3931-650X

Phone: 352-265-0494

FAX: 352-265-0676

Email: philip.efron@surgery.ufl.edu

Rhonda Bacher, Ph.D.

Department of Biostatistics, University of Florida

Gainesville, Florida 32610-0019

Email: rbacher@ufl.edu

Keywords: myeloid-derived suppressor cells, sepsis, transcriptomics, single-cell RNA sequencing, chronic critical illness

Word count: 6869

Figure and Table Count: 14

47 **Abstract**

48
49 Sepsis engenders distinct host immunologic changes that include the expansion of myeloid-
50 derived suppressor cells (MDSCs). These cells play a physiologic role in tempering acute
51 inflammatory responses but can persist in patients who develop chronic critical illness. The
52 origins and lineage of these MDSC subpopulations were previously assumed to be discrete and
53 unidirectional; however, these cells exhibit a dynamic phenotype with considerable plasticity.
54 Using Cellular Indexing of Transcriptomes and Epitopes by Sequencing followed by
55 transcriptomic analysis, we identify a unique lineage and differentiation pathway for MDSCs
56 after sepsis and describe a novel MDSC subpopulation. Additionally, we report that the
57 heterogeneous response of the myeloid compartment of blood to sepsis is dependent on clinical
58 outcome.
59

60 **1 Introduction**

61
62 Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host
63 response to infection (1), with survivors experiencing either a rapid recovery or chronic critical
64 illness (CCI) (2). The emergency myelopoietic response to sepsis is characterized by
65 hematopoietic stem and progenitor cell (HSPC) expansion and preferential differentiation along
66 myeloid pathways (3-7). We and others have previously demonstrated that sepsis induces an
67 expansion of circulating myeloid-derived suppressor cells (MDSCs), and that both an increase in
68 and persistence of specific MDSC subpopulations are seen in sepsis patients with poor clinical
69 outcomes (4, 8, 9).

70 Three MDSC subpopulations are typically described based on cell surface expression,
71 mechanisms of immune suppression, and inflammatory profiles: granulocytic (PMN-),
72 monocytic (M-), and early (E-) MDSCs (10, 11). Although these MDSCs differ phenotypically,
73 they are all capable of suppressing T-lymphocyte proliferation (4, 12). As research into the
74 myeloid compartment during inflammation expands, the complexity of intermediate cell types is
75 just beginning to be understood. Indeed, Hegde et al. recently concluded that suppressive
76 myeloid cell types, including MDSCs, “*are highly heterogeneous and context dependent*” (13).
77 The authors presented an emergent view of MDSCs that emphasizes heterogeneity and plasticity
78 in contrast to the classical view of MDSCs as the midpoint in a differentiation pathway that
79 results in terminally-differentiated monocytes and granulocytes (13).

80 Single-cell RNA-sequencing (scRNA-seq) details the transcriptomes of complex and
81 heterogeneous cell mixtures. An extension of this technique, Cellular Indexing of
82 Transcriptomes and Epitopes by Sequencing (CITE-seq), simultaneously profiles cell surface
83 proteins for each cell. We initially performed CITE-seq in order to identify MDSC
84 subpopulations based on cell surface makers/cell phenotypes, as our previous results (14)
85 indicated that MDSCs from septic patients may not express some of the classic genes found in
86 MDSCs from cancer patients, making them difficult to identify. We compared the transcriptomes
87 of myeloid cells from healthy subjects, acutely septic patients, and patients with good and poor
88 clinical outcomes at later time points after sepsis. We found that MDSC subpopulations evolve
89 over time and that outcome-dependent MDSC subpopulations exist. Specifically, we identified a
90 novel hybrid (H)-MDSC phenotype unique to some sepsis survivors with poor clinical outcomes
91 as well as acutely septic patients that progressed to CCI. Additionally, our findings suggest that
92 the proliferation and cytokine production of lymphocytes, when co-cultured with MDSCs, vary
93 at different time points after sepsis. Importantly, MDSCs do not express key genes seen in cancer
94 whose downstream products suppress T-cell responsiveness. Overall, our results demonstrate a
95 critical need for disease- or “context-” specific understanding of MDSCs when considering host-
96 specific immune dysfunction and potential therapies.

97 **2 Materials and Methods**

98 **2.1 Study Design**

99
100 Our study design was previously reported by Darden, et al (14). To summarize, this
101 prospective, observational cohort study was registered with *clinicaltrials.gov* (NCT02276417)
102 and conducted at a tertiary care, academic research hospital. The objective of the study was to
103 better understand the myeloid response (specifically blood MDSCs) to acute sepsis, and to
104 identify transcriptomic differences in sepsis patients who rapidly recover versus those who
105
106

107 develop CCI. Our hypothesis was that differences in the myeloid transcriptomic landscape could
108 explain why some sepsis patients rapidly recover while others develop CCI.

109 Sepsis designation occurred through an electronic medical record-based Modified Early
110 Warning Signs-Sepsis Recognition System (MEWS-SRS), which uses white blood cell count,
111 heart rate, respiration rate, blood pressure, and mental status to identify patients at-risk for sepsis.
112 All patients with sepsis were treated with early goal-directed fluid administration, initiation of
113 broad-spectrum antibiotics, and vasopressor administration if appropriate. Antibiotic treatment
114 was tailored to culture results and antibiotic resistance information.

115 Inclusion criteria:

116 Admission to the intensive care unit (ICU)
117 Age >17 years
118 Diagnosis of sepsis or septic shock according to the 2016 SCM/ESICM
119 International Sepsis Definitions Conference (1)
120 Initial septic episode while hospitalized
121 Management of patient via the sepsis clinical management protocol (15)

122 Exclusion criteria:

123 Refractory shock
124 Inability to achieve source control
125 Pre-sepsis expected lifespan <3 months
126 Expected withdrawal of care
127 Severe congestive heart failure (NYHA Class IV)
128 Child-Pugh Class C liver disease or undergoing evaluation for liver
129 transplant
130 HIV infection with CD4⁺ count <200 cells/mm³
131 Prior organ transplant, use of chronic steroids, or immunosuppressive
132 agents
133 Pregnancy
134 Institutionalized or other vulnerable patients
135 Chemotherapy or radiotherapy treatment within 30 days of sepsis onset
136 Severe traumatic brain injury (defined by radiologic evidence and GCS <8)
137 Spinal cord injury with permanent deficits
138 Unable to obtain informed consent

139 CCI was defined as ICU length of stay >13 days with persistent organ dysfunction as
140 measured by the Sequential Organ Failure Assessment (SOFA) Score. Patients were also
141 designated CCI with <14 days ICU length of stay if they were transferred to another hospital, or
142 discharged to a long-term acute care facility or hospice with evidence of persistent organ
143 dysfunction (4, 16). Patients were excluded from analysis if they died within 14 days of onset of
144 sepsis (4, 16).

145

146 **2.2 Human blood collection and sample preparation**

147

148 Whole blood samples were collected at the following time points: 4 ± 1 days and 14-21
149 days after sepsis (16). For the former, we enrolled four patients diagnosed with septic shock (1)
150 in order to guarantee a strong host response and transcriptomic alterations in circulating
151 leukocytes. Interestingly, only half of these septic shock patients went on to develop CCI; the
152 mortality for this cohort was 50% (17, 18). Samples from five patients who developed CCI and

153 four patients who rapidly recovered after sepsis were obtained from additional patients between
154 days 14-21 after sepsis diagnosis. We previously determined this time point to be key to MDSC
155 differentiation as well as distinguishing CCI from rapid recovery (4, 16). In addition, whole
156 blood was collected from 12 healthy subjects (1, 2). The proportion of men and women did not
157 differ between sepsis patients and healthy subjects. Healthy subjects trended towards being
158 younger than sepsis patients, although they still met the criteria of middle age (>45 years),
159 encompassing patients who have poor outcomes after sepsis compared to younger cohorts (17,
160 18). Healthy subjects and septic patients had similar comorbidity scores, and similar underlying
161 comorbidities (most commonly hypertension, chronic obstructive pulmonary disease, and
162 diabetes mellitus).

163 Each blood collection underwent two enrichment procedures. PBMCs were collected
164 from half of each sample using Ficoll-PaqueTM PLUS (Millipore Sigma, St. Louis, MO) and
165 density gradient centrifugation. Myeloid cells were collected using RosetteSepTM HLA Myeloid
166 Cell Enrichment Kit (STEMCELL Technologies, Vancouver). A 1:3 mixture of enriched
167 PBMCs: myeloid cells was created in order to adequately analyze the small target population
168 (MDSCs, especially in control subjects) while also allowing for characterization of other
169 important immune cell populations using CITE-seq.

170

171 **2.2.1 Human T-cell isolation and proliferation assay**

172

173 Total T cells in the PBMC suspension were captured by immunomagnetic negative
174 selection using EasySepTM Human T Cell Isolation Kit (STEMCELL Technologies, Vancouver)
175 according to the manufacturer's instructions. Isolated CD3⁺ lymphocytes were labeled with cell
176 trace violet (Thermo Fisher, Waltham, MA) to assess T-cell proliferation. T lymphocytes (1×10^5
177 CD3⁺) were seeded into a 96-well plate and stimulated with soluble anti-CD3/CD28
178 antibodies (STEMCELL Technologies, Vancouver) or without, which served as the control.
179 CD66b⁺ cells were also isolated from the PBMC fractions using EasySepTM positive selection kit
180 (STEMCELL Technologies, Vancouver) and were co-cultured with stimulated T cells in a 1:1
181 ratio at 37°C and 5% CO₂. After 4 days, cells were harvested and supernatants were obtained for
182 cytokine analysis. Cells were stained with anti-CD8 FITC and anti-CD4 PE and analyzed via
183 flow cytometry (ZE5 Cell Analyzer, Bio-Rad Laboratories, CA). Proliferation indices were
184 calculated as the total number of cell divisions divided by the number of cells that went into
185 division (considering cells that underwent at least one division).

186

187 **2.2.2 Cytokine analysis**

188

189 Human high sensitivity T cell magnetic bead 6-plex panels (IFN- γ , IL-10, IL-12 (p70),
190 IL-17 α , IL-2, IL-23) were purchased from EMD Millipore (Billerica, MA). Supernatants after
191 cell culture were used for T cell-associated cytokines. The xPONENT software (EMD Millipore,
192 Billerica, MA) was used for cytokine analysis.

193

194 **2.2.3 Flow cytometry**

195

196 PBMC samples were analyzed fresh (not frozen and rethawed) due to differential
197 viability of cell populations, particularly granulocytes.(19, 20) Although the PBMC fraction
198 excludes mature granulocytes, it does contain low-density granulocytes that are presumed to

199 include PMN-MDSCs (21). Classically, human blood MDSCs are defined from PBMCs as: M-
200 MDSCs (CD11b⁺CD14⁺CD33⁺HLA⁻DR^{low/-}) and PMN-MDSCs (CD11b⁺CD15⁺HLA⁻
201 DR^{low}CD66b⁺) (22). Our preliminary flow cytometric analysis revealed that CD15 was not a
202 good cell surface marker to isolate CD14⁻ cells from PBMCs (**Fig. S1C**). In fact, the analysis of
203 CD33⁺CD11b⁺HLA⁻DR^{low/-} cells revealed heterogeneity in CD14 and CD15 cell surface
204 expression. Thus, we chose to isolate CD66b⁺ cells from PBMCs to obtain PMN-MDSCs (**Fig.**
205 **S1C**).

206

207 **2.3 Statistics**

208

209 **2.3.1 scRNA-seq read preprocessing**

210

211 Gene expression and feature-barcoding data were generated using 10x Genomics v1.1 5'
212 chemistry and were sequenced on an Illumina HiSeq® with a target of 10,000 cells per sample
213 (23). The **Cell Ranger** (10X Genomics) software suite was used to process base calls into
214 FASTQ files, which were checked for quality control aberrations using **FastQC** v0.11.7 (24). A
215 spliced + intronic, or *bplice*, reference transcriptome was generated from the hg38 reference
216 genome (25). Reads were pseudoaligned to the reference transcriptome with **alevin-fry** v 0.8.1;
217 USA mode was used for gene expression reads in order to provide separate quantifications of
218 spliced, unspliced, and ambiguous mRNA abundance (26-28). The counts of 11 cell surface
219 proteins of interest were also quantified using **alevin-fry**. Splicing-aware gene expression
220 quantification was performed using Ensembl transcript IDs, with final counts matrices
221 aggregated using Ensembl gene IDs.

222

223 **2.3.2 scRNA-seq data processing**

224

225 Downstream data processing and analysis were performed primarily in R v4.2.3, with
226 some additional processes written in Python v3.8 as required (29, 30). After loading the
227 unfiltered spliced, unspliced, and ambiguous mRNA counts into R using **fishpond** package
228 v2.4.1, we defined total mRNA counts as the elementwise sum of all three counts matrices and
229 added the ambiguous counts to the spliced counts matrix (31). Unless otherwise specified, total
230 mRNA counts were used as input throughout the analysis. Empty droplets and ambient mRNA
231 were then identified and filtered out using the **DropletUtils** package v1.18.1 (32, 33). Cells with
232 an estimated false discovery rate of <0.01 were kept for each sample. Next, the percentage of
233 spliced reads coming from mitochondrial genes was computed for each cell, and cells with less
234 than 5% mitochondrial DNA were kept (no significant difference between healthy and septic
235 samples). Cell surface protein counts were imported as well, and cells that had valid gene
236 expression barcodes but not protein barcodes were assigned a value of “0” for each protein. The
237 raw counts matrices were then formatted and merged using the **Seurat** package v4.3.0, providing
238 a single object with total, unspliced, and spliced mRNA as well as cell surface protein assays
239 (34). Cells with less than three spliced and unspliced transcripts were removed by filtering; thus,
240 the final merged dataset comprised 28,952 genes and 119,062 cells.

241 The total mRNA counts were scaled by library size factors and log_{1p}-normalized, while
242 protein counts were normalized via a centered log ratio transformation across each gene. Four
243 thousand highly variable genes (HVGs) were identified using a local polynomial regression
244 between the log of expression variance and the log of mean expression as implemented in the

245 **FindVariableFeatures** function. After scaling the normalized counts, 100 principal components
246 were computed using the set of HVGs as input, and each cell was scored and assigned a cell
247 cycle phase as described previously (35). Next, the 25 different samples were integrated by the
248 **Harmony** package v0.1.1, which corrects the existing Principal Component Analysis (PCA)
249 embedding (36). The first 50 principle components were used as input, and a two-dimensional
250 UMAP embedding was computed using the cosine distance on the resulting 50 Harmony
251 components (37). Lastly, an approximate shared nearest neighbors graph was computed on the
252 first 50 Harmony components using the cosine distance with the number of nearest neighbors set
253 to 100, and the resulting graph was partitioned into clusters via Louvain modularity optimization
254 using a resolution of 0.1 (38).

255

256 **2.3.3 scRNA-seq annotation**

257

258 After clustering, the **SingleR** package v2.0.0 was used with several different immune
259 reference datasets with known labels to assign a most-likely broad cell type to each cluster (39-
260 44). In addition, the **Azimuth** package was used to map reference labels from an annotated
261 dataset of healthy human PBMCs to each cell at multiple levels of granularity (34). Lastly,
262 between-cluster differential expression testing was performed using the Wilcoxon rank-sum test
263 with p -values adjusted via the Bonferroni correction. Genes were considered for testing if they
264 were expressed by at least 25% of the cells in the cluster being tested, and results were retained if
265 the mean log₂ fold-change was greater than 0.25 and the adjusted p -value was less than 0.05 (45,
266 46). After a comparison of the resulting differentially expressed gene sets (DEGs) with canonical
267 marker genes from the literature and an investigation of the unsupervised annotations, a broad
268 cell type identity was manually assigned to each cluster.

269 After subsetting the initial dataset to just the cluster labeled as monocytes, cells with
270 confident T-cell labels from Azimuth were filtered out and the data were split into two groups
271 based on whether the cells came from healthy subjects or septic patients. Subcluster analysis was
272 performed on the monocytes from the healthy subjects and septic patients. Briefly, the data were
273 reprocessed and reintegrated as described before, though the number of HVGs was lowered to
274 3,000 and only 30 principal components were used as input to the integration, nonlinear
275 dimension reduction, and clustering routines. In addition, the number of estimated nearest
276 neighbors was reduced based on the smaller sizes of the subsets. Any further subclustering of
277 heterogeneous cell types was performed using the same methods. Differential expression testing
278 was again used to identify potential marker gene sets, and a fine cell type label was manually
279 assigned to each cluster. Lastly, the cell type labels were subjected to confirmatory analysis
280 using the available cell surface protein data as needed.

281

282 **2.3.4 scRNA-seq differential expression**

283

284 Differential expression testing between for each time point versus healthy subjects in the
285 “classically” annotated MDSCs was performed using a pseudobulk approach. Counts across all
286 cells for each patient were aggregated and summed, then the DESeq2 method was applied for
287 differential testing using the muscat R package v1.14.0 (47). The cell-type specific marker gene
288 expression testing on the MDSCs annotated using the “emergent” view was performed using the
289 **FindAllMarkers** function in Seurat using the wilcox method.

290 Differentially expressed testing between sepsis groups was performed using linear mixed
291 models. Each gene was tested between comparison groups for M-MDSCs, as they were the only
292 population of MDSCs with a sufficient number of cells ($n > 50$) per group. Normalized
293 expression was used as the response, with a binary indicator for sepsis group as the sole fixed
294 effect. A random intercept was included for each sample, and models were fit via the maximum
295 likelihood estimation using the **MixedModels.jl** Julia package (48, 49). After recording
296 expression statistics such as mean expression per group, raw fold change, and log₂ fold change,
297 the p -value of the group difference fixed effect from the linear mixed model was used to
298 determine the significance of differential expression after adjustment using the Holm correction
299 (38, 50).

300

301 **2.3.5 Enrichment of genes with high transcriptional activity in MDSCs**

302

303 The unspliced ratio per gene per cell was calculated as (unspliced counts + 1) divided by
304 the (spliced counts + 1), then the mean for each gene was calculated separately for the MDSC
305 subpopulations. Genes having a mean ratio greater than 1.1 were considered as having a high
306 degree of active transcription. The **gprofiler2** R package v0.2.1 (51) was used to identify
307 significantly enriched biological processes for each set of genes, then a network-based approach
308 was performed to better understand the biological functions using the **vissE** R package v1.8.0
309 (52). Similarities among the enriched processes were computed using the Jaccard index and then
310 used to build an overlap network. Clusters of enriched gene-sets were identified by graph
311 clustering; for each cluster a frequency analysis of words in the gene-set names indicates the
312 most relevant biological functions.

313

314 **2.3.6 scRNA-seq trajectory inference and RNA velocity**

315

316 After annotating the septic monocytic cells, the data were further subject to only include
317 the cell types thought to be relevant to MDSC development and differentiation: classical and
318 non-classical monocytes, cDCs, and MDSCs. This subset was re-embedded using UMAP, and
319 the cells were reclustered using the re-computed simulated neural network graph as input to the
320 Louvain algorithm (37). After extracting the UMAP parameters from the output of the
321 **RunUMAP** function, we used the **uwot** R package to regenerate the fitted UMAP model and
322 nearest neighbor data that were generated internally (53). From this output we extracted the
323 UMAP connectivity graph, which is a sparse representation of the fuzzy simplicial data set that
324 can be loosely interpreted as a metric of how likely connections are between cells (37). The raw
325 counts matrices, metadata for cells and genes, nearest neighbor graphs, PCA, Harmony, and
326 UMAP embeddings, and the UMAP connectivity graph were used to generate an **AnnData**
327 object in Python that exactly matched the preprocessing used when annotating the cells in R (54).

328 The preprocessed data were used as input to an RNA velocity estimation workflow built
329 around the **scVelo** package v0.2.5. After computing first-order moments of the spliced and
330 unspliced counts, the dynamical velocity model was used to estimate per-gene velocities and a
331 cell-level velocity graph, after which the velocities were projected onto the existing UMAP
332 embedding (55, 56). Next, transition probability matrices, absorption probabilities, and initial
333 and terminal cell state likelihoods were estimated based on a weighted kernel of the velocity
334 estimates and UMAP connectivities using the **CellRank** package v1.5.1 (57). The resulting cell
335 fate probabilities then served as a prior for the estimation of a gene-shared latent time for each

336 cell. Lineage driving genes were identified by estimating the Spearman correlation of each
337 gene's expression with absorption probabilities for each identified cell fate. Finally, a directed
338 partitioned graph abstraction was estimated and projected into the existing UMAP embedding
339 using the state probability and latent time estimates as priors; these computations were
340 performed using the partition-based graph abstraction (PAGA) algorithm as implemented in
341 v1.9.3 of the **Scanpy** package (58, 59). In addition, an undirected graph abstraction was used as
342 the initialization for a force-directed graph embedding of the cells, after which the graph
343 abstraction was recomputed on the resulting embedding. This layout of the cells was used to
344 display inter-cell type connectivities, which were estimated as described previously using UMAP
345 (60, 61).

346 Differences in the dynamical model parameters (state probabilities, velocity length and
347 pseudotime, cell stability index, and lineage priming) were tested between septic groups within
348 MDSC subpopulations using a linear mixed model. Specifically, the **nlme** R package v3.1-162
349 (62) was used to fit a model with fixed effects of cell type, group, and their interaction, and a
350 random intercept for subject. Pairwise testing was then obtained using contrasts of interest
351 (across groups within cell type) with the **emmeans** R package v1.8.7 (63).

352

353 **3. Results**

354

355 **3.1 MDSC subpopulations initially defined by classical cell surface markers**

356

357 Here we have used CITE-seq to analyze single-cell transcriptomic profiles of MDSCs in
358 blood from healthy subjects (n=12) and surgical sepsis patients at 4 ± 1 (n=4) and 14-21 (n=9)
359 days after sepsis onset (64). Septic patients at 14-21 days were further divided based on their
360 clinical outcomes at time of sampling, defined as either 'rapid recovery' (n=4) or development of
361 CCI (n=5). CCI was defined as sepsis survivors requiring 14 or more days of ICU care with
362 persistent organ injury. Sex, age, BMI, and comorbidity profiles were similar between cohorts
363 (**Table 1**).

364 Similar to flow cytometry phenotyping, CITE-seq employs conventional cell surface
365 markers for myeloid cell subpopulations to define E-MDSCs ($\text{Lin}^- \text{HLADR}^{\text{low/-}} \text{CD33}^+ \text{CD11b}^+ \text{CD14}^- \text{CD15}^- \text{CD66b}^-$), PMN-MDSCs ($\text{Lin}^- \text{CD33}^+ \text{CD11b}^+ \text{CD14}^-$ and CD15^+ or CD66b^+), and M-MDSCs ($\text{Lin}^- \text{HLADR}^{\text{low/-}} \text{CD33}^+ \text{CD11b}^+ \text{CD14}^+ \text{CD15}^- \text{CD66b}^-$), as well as
367 $\text{CD14}^+ \text{CD16}^-$ (classical) and $\text{CD14}^{\text{dim}} \text{CD16}^+$ (non-classical) monocytes (while removing
368 platelets, erythrocytes, HSPCs, $\gamma\delta$ T cells, and innate lymphoid cells). This is consistent with the
369 classical monolithic view of myeloid differentiation described by Hegde (**Fig. 1A**) (13).
370 Historically, flow cytometry classification of MDSCs is performed directly on isolated PBMCs
371 (4, 16), and our analysis revealed that PMN-MDSCs made up the majority of MDSCs in isolated
372 PBMCs of representative septic patients, consistent with prior literature (**Table 2**) (4, 16).

373 We then evaluated cell proportions using transcriptomics with confirmation via flow
374 cytometry. Myeloid cell enrichment was necessary in this step in order to detect MDSCs in
375 healthy subject samples during CITE-seq as they are a relatively rare population (*see Methods*
376 *Section entitled "Human Blood Collection and Sample Preparation"*). Both single-cell
377 transcriptomics and flow cytometry revealed an overall increase in total MDSCs acutely after
378 sepsis (**Fig. 1B and Table 3**). We plotted the cells via Uniform Manifold Approximation and
379 Projection (UMAP) based on timepoint after sepsis (**Fig. 1C**) and myeloid cell subtype (**Fig.**
380 **1D**), which revealed heterogeneity of these cells when analyzing their single cell transcriptomes.
381

382 The classification of MDSCs based on cell surface phenotypes is somewhat dependent on the
383 method of analysis, and as the myeloid enrichment kit (STEMCELL) uses CD33 (and CD33 is
384 expressed on all MDSCs), this was our first inclination that an alternative method of classifying
385 cells by subpopulation would be necessary.

386 Next, we performed pseudobulk differential gene expression between septic patients at
387 day 4 and days 14-21 post-sepsis diagnosis compared to healthy subjects to assess possible
388 differences among septic groups. Dramatic differences in gene expression within MDSC
389 subpopulations (specifically PMN- and M-MDSCs, which were most abundant) were observed
390 that varied over time (**Fig. 2**). Considering PMN-MDSCs, by comparing each differential
391 expression test performed against healthy subjects, we found more extreme fold-changes in late
392 sepsis patients who developed CCI compared to acutely septic patients (**Fig. 2A, left panel**).
393 Conversely, gene expression for late sepsis patients who rapidly recovered returned towards that
394 seen in healthy subjects when compared to both acute sepsis and late sepsis with CCI. Gene
395 expression for rapid recovery and CCI patients compared to healthy subjects also tended to
396 diverge (**Fig. 2A, middle and right panels**). Overall, 52 genes were differentially expressed in
397 PMN-MDSCs from acutely septic patients; however, only three of these genes were also
398 significantly differentially expressed in both late sepsis patients who either rapidly recovered or
399 developed CCI (**Fig. 2B; Supplemental File 1**). The ontology of transcriptional differences
400 among septic patients at different time points also illustrated the heterogeneity of the PMN-
401 MDSC response over time (**Fig. 2C**).

402 The greatest differences in the magnitude of M-MDSC gene expression from healthy
403 subjects compared to septic patients occurred during acute sepsis (day 4) (**Fig. 2D**). In this
404 cohort, 601 genes were differentially expressed in M-MDSCs, and only 31 of these were also
405 significantly differentially expressed in late sepsis patients who either rapidly recovered or
406 developed CCI at days 14-21 (**Fig. 2E**). Gene ontology analysis among M-MDSCs revealed that
407 patients experiencing rapid recovery had over-expression of kinase agents versus oxoacid
408 metabolism when compared to sepsis patients with CCI (**Fig. 2F**).

409 In summary, transcriptomic analysis comparing healthy subjects, patients day 4 post-
410 sepsis, and patients at days 14-21 post-sepsis (combining those who rapidly recovered with those
411 who developed CCI) revealed significant heterogeneity in MDSC transcriptomics. In addition,
412 lymphocyte suppressive activity, specifically suppression of T cell proliferation and T cell
413 cytokine/chemokine production, varied between cohorts (*see below*). MDSCs from both time
414 points after sepsis were dissimilar when comparing their gene expression profiles and
415 significantly enriched biological processes from gene ontology.

416

417 **3.2 Verifying the immunosuppressive capacity of MDSCs present in sepsis**

418

419 Our laboratory has previously used cell sorting and subsequent T-cell suppression assays
420 to demonstrate the immunosuppressive capacity of total MDSCs from septic patients (4, 16).
421 Thus, we set out to verify that functionally active PMN- and M-MDSCs were indeed present in
422 the isolated peripheral blood mononuclear cells (PBMCs) of septic individuals, as defined by
423 Gabrilovich, et al (65). Surprisingly, we discovered unexpected cell types in our flow cytometry
424 samples that were supported by single-cell analysis. Historically in the cancer literature, CD15
425 positivity is used to distinguish PMN-MDSCs from M-MDSCs (13). However, in representative
426 septic patients, after identifying CD11b⁺CD33⁺ cells (**Fig. S1A**) and isolating HLA-DR^{-low} cells
427 to obtain the total MDSC population (**Fig. S1B**), CD15 was unable to clearly separate MDSC

428 subpopulations (**Fig. S1C, bottom panel**). Alternatively, CD66b (*CEACAM8*; a granulocytic
429 marker) was able to better delineate MDSC subpopulations (**Fig. S1C, top panel**) and, thus, was
430 selected to distinguish PMN-MDSCs from PBMCs for functional analysis (**Fig. S1D**) (19, 20,
431 65-67). We undertook bulk CD66b⁺ cell isolation (STEMCELL Technologies, Vancouver);
432 however, although CD14⁻CD15⁺ PMN-MDSCs enrichment was achieved, further analysis of the
433 CD66b⁺-isolated cells demonstrated distinct CD66b^{low} and CD66b^{high} populations (**Fig. S2A**).
434 Thus, we had enriched CD66b^{low}CD14⁺CD15⁻ M-MDSCs in our gating strategy which was
435 meant to only contain PMN-MDSCs (CD66b^{high}) (**Fig. S2B**).

436 Functionally, the CD66b⁺ cells isolated from septic patient PBMCs suppressed either
437 CD4⁺/CD8⁺ T-lymphocyte cytokine/chemokine production (**Fig. S3**) or lymphocyte proliferation
438 of host CD8⁺ T-lymphocytes (**Fig. S4**), thereby meeting the criteria of MDSCs. CD66b⁺ MDSCs
439 from septic but not healthy subjects altered T-cell cytokine production in response to
440 antiCD3/CD28 treatment, including IFN- γ , IL-2, IL-4, IL-10, and IL-17 (**Fig. S3**). Cytokines
441 which were analyzed which did not exhibit CD66b⁺ inhibition in acutely septic patients include
442 IL-12, IL-23, and TGF- β . Only CD66b⁺ cells isolated from sepsis patients 14-21 days after
443 infection were capable of significantly suppressing CD8⁺ T-lymphocyte proliferation in response
444 to CD3/CD28 stimulation (**Fig. S4**). Although we did not see suppression of CD4⁺ T-lymphocyte
445 proliferation by CD66b⁺ cells in response to CD3/CD28 stimulation, we did see a significant
446 decrease in CD4⁺ T-lymphocyte proliferation stimulated in culture at days 14-21 compared to
447 day 4 (**Fig. S5**). This indicates that CD4⁺ T lymphocytes are incapable of appropriate
448 proliferation 2-3 weeks after sepsis (similar to what has been previously reported) (68), and that
449 MDSCs at this time point may not be able to further suppress this aspect of CD4⁺ T lymphocyte
450 function (22, 68).

451 452 **3.3 Emergent view of MDSCs and transcriptomic analysis of a novel MDSC** 453 **subpopulation**

454
455 After our initial steps demonstrated that identification of MDSC subsets based on cell
456 surface markers was potentially problematic in sepsis, we transitioned to cell classification via
457 gene expression for the remainder of our analysis. All cells were clustered based on their
458 transcriptomic profiles (visualized via UMAP (**Fig. 3A**) with relative percentages of each cell
459 type depicted in **Fig. 3B**). The broad cell types were compared via expression of cell-surface
460 marker genes (**Fig. 3C**) as well as percentage of spliced mRNA between patient groups (**Fig.**
461 **3D**). This was followed by careful manual annotation and inspection of canonical marker genes
462 with identification of myeloid cells via differential expression of genes (**Fig. 4**). As explained by
463 Hegde, et al. (13), there is substantial plasticity within MDSC subpopulations during sepsis
464 which informs the relationship between MDSCs and terminally differentiated effector cells (**Fig.**
465 **5A**). Additional marker genes were used to obtain fine-level annotation of myeloid cell types
466 (**Fig. 5B**). Importantly, four distinct populations of MDSCs were identified via this approach
467 (**Fig. 5C**), three of which were consistent with classically defined E-, PMN-, and M-MDSCs
468 (65). A novel fourth population was identified in 60% of the late sepsis patients who developed
469 CCI, as well as both of the acutely septic patients who progressed to CCI (**Table 4, Fig. 6A**).
470 This MDSC subpopulation exhibited gene expression patterns that were partially consistent with
471 both M- and PMN-MDSCs. We thus labeled these cells "*hybrid*" (H)-MDSCs. Although one of
472 the patients with CCI had a much greater number of H-MDSCs than other patients, it should be

473 noted no H-MDSCs were observed in late sepsis patients who had rapidly recovered, or acutely
474 septic patients who progressed to rapid recovery (**Table 4**).

475 The majority of MDSC-specific genes in septic patients were shared by at least two of the
476 four subpopulations (66%, n=270 genes), with 36% (n=147 genes) significantly expressed by all
477 four (**Fig. 6B, Supplemental File 2**). Although the MDSC subpopulations were fairly similar in
478 terms of overlapping genetic expression, we identified seven genes uniquely expressed by H-
479 MDSCs: *RGDP5*, *TBLIX*, *MBNL1*, *SERF2*, *ATP5F1E*, *MT-ND1*, and *MT-ATP6* (**Fig. 6C**). Gene
480 expression was downregulated in RANBP2-like and GRIP domain-containing protein 5
481 (*RGDP5*), transducin (beta)-like 1X-linked (*TBLIX*), and muscleblind-like splicing regulator 1
482 (*MBNL1*) (69, 70). *TBLIX* regulates transcriptomic pathways and is upregulated in malignancy
483 (69). *MBNL1* regulates alternative splicing and can be up- or downregulated depending on the
484 type of cancer (71). Genes with upregulated expression included small EDRK-rich factor 2
485 (*SERF2*), ATP synthase F1 subunit epsilon (*ATP5F1E*), NADH-ubiquinone oxidoreductase
486 chain 1 (*MT-ND1*), and mitochondrially encoded ATP synthase membrane subunit 6 (*MT-
487 ATP6*). The latter three genes encode proteins involved in mitochondrial metabolism and
488 function (72).

489 We next sought to identify differential genetic expression between our septic cohorts,
490 specifically looking at differences between MDSCs in late sepsis patients who rapidly recovered
491 and those who developed CCI. For differential expression across sepsis groups, only M-MDSCs
492 were sufficiently present per group for fitting a linear mixed model with multiple subjects, as
493 MDSCs are a relatively rare population overall. We identified four differentially expressed genes
494 in M-MDSCs using this method: *CD163*, *IER2*, *CTSZ*, and *SNX3* (**Fig. 6D**). Expression of
495 *CD163* (73), a gene responsible for controlling inflammation, was significantly lower in M-
496 MDSCs in late sepsis patients with CCI versus acutely septic patients. *SNX3* has been identified
497 as a potential septic biomarker (74), and was significantly upregulated in patients with CCI
498 compared to acutely septic patients. *IER2* was significantly higher expressed in late sepsis
499 patients who rapidly recovered compared to acutely septic patients. *IER2* is known to be
500 upregulated in response to external stimuli including infection (75, 76). *CTSZ* expression was
501 significantly higher in patients with CCI compared to patients who rapidly recovered after sepsis,
502 and has been previously identified as a septic marker in mice (77).

503 The plasticity of the H-MDSC subpopulation is evident in the increased per-cell
504 proportion of unspliced mRNA, indicating more active transcription. Only E-MDSCs had a
505 higher proportion of unspliced mRNA in the myeloid compartment (**Fig. 7A**). To examine
506 factors driving cellular activities, we identified genes with a high average proportion of unspliced
507 mRNA within each cell subpopulation and performed enrichment analysis to identify relevant
508 biological processes. Rather than focusing on individual ontologies, we used a network-based
509 approach to cluster similar significantly enriched biological functions for each MDSC
510 subpopulation (**Fig. 7B-E**) (52). Not surprisingly, actively transcribed genes in all MDSC
511 subpopulations were enriched for activities pertaining to ‘immune activation.’ While PMN- and
512 M-MDSCs had more biologically distinct functions, H-MDSCs shared enrichment with both cell
513 types, specifically pertaining to pathophysiological septic-related processes including
514 ‘organonitrogen’ and phosphorus-related processes.

515 516 **3.4 Determination of differentiation pathways and cell lineage in septic cohorts**

517

518 Having described the MDSC subpopulations, we next set out to incorporate these
519 findings into differentiation pathways of the myeloid compartment in septic patients. Quantifying
520 transcriptional kinetics via RNA velocity estimation revealed complex, fluid relationships
521 between MDSC phenotypes (**Fig. 8A**). As expected, M-MDSCs appeared to serve as the bridge
522 between early immunosuppressive cell types and mature myeloid cells such as monocytes and
523 conventional dendritic cells (cDCs) (**Fig. 8B**). As our analysis was based on PBMCs, it was not
524 possible to compare the transition from MDSCs to mature granulocytes (PMNs). Estimating the
525 graph connectivity between monocyte-lineage cell types allowed us to quantify the strength of
526 each undirected relationship, and showed that MDSC subpopulations are both highly
527 interconnected and much more internally similar to each other than they are to populations of
528 terminally-differentiated myeloid cells (**Figs. 8B-C**).

529 After analyzing velocity-inferred cell state transitions performed with **CellRank**, all E-,
530 PMN-, and the vast majority of M-MDSCs cell states were classified as progenitor-like or
531 transitioning-like (**Fig. 8D**). Only H-MDSCs contained a significant proportion of cells in a
532 plasticity-like state with high probabilities for both initial and terminal cell states (in which cells
533 remain H-MDSCs) (**Fig. 8E**) (57). Supporting this, significant variation was observed in the
534 likelihood of an H-MDSC staying an H-MDSC when estimated by absorption probabilities from
535 **CellRank**, with a mean (SD) probability of 0.33 (0.29) (**Fig. 8F**). No other cell types were likely
536 to end up as H-MDSCs. To better characterize the biology underlying commitment to the H-
537 MDSC cell fate, lineage driver genes (genes significantly correlated with the probability of
538 becoming an H-MDSC) were identified by computing Spearman correlations of expression with
539 absorption probabilities. Highly correlated genes were diverse in function and included
540 inflammation-associated genes such as *S100A8*, *-9*, and *-12*, along with immunoregulatory genes
541 *ALOX5A*, *RETN*, and *IL1R2*.

542 Next, we investigated differences in cell states across sepsis groups for each MDSC
543 subpopulation. As H-MDSCs were not observed in sepsis patients who experienced rapid
544 recovery, they were not included for this analysis. M-MDSCs were highly consistent between
545 septic patients at day 4 and days 14-21 in terms of their cell states and kinetics (**Fig. 9A**).
546 Interestingly, PMN-MDSCs displayed the most heterogeneity, specifically in late sepsis patients
547 with CCI compared to both day 4 septic patients and late sepsis patients who rapidly recovered.
548 PMN-MDSCs in late sepsis patients who developed CCI had significantly slower differentiation
549 speed, higher cell state stability, and lower initial state probabilities (**Fig. 9B**). This is consistent
550 with PMN-MDSCs persisting in CCI compared to patients who rapidly recover after sepsis. E-
551 MDSCs in late sepsis patients with CCI also showed significantly lower differentiation
552 progression than acutely septic patients or late sepsis patients who rapidly recovered, along with
553 a higher degree of cell commitment along the differentiation trajectory compared to acutely
554 septic patients (**Fig. 9C**).

555 As previously stated, CD66b⁺-isolated PBMCs met the criteria of MDSCs in their ability
556 to suppress either T-lymphocyte cytokine/chemokine production or T-lymphocyte proliferation
557 *ex vivo* (**Figs. 5 & 6**) (4, 16), although CD66b⁺-isolated PBMCs were not identical in their
558 suppressive activity from acutely septic patients or late time periods after severe infection.
559 Interestingly, whether using cell-surface markers or transcriptomic analysis of the current
560 dataset, differential expression of several key MDSC genes published in the cancer literature did
561 not reach significance and/or were modestly expressed in septic individuals (**Fig. 10**). For
562 example, although there was upregulation of genes in the *S100A* and *MMP* superfamilies,

563 differential expression of *ARG1*, *IL-10*, *NOS2*, and *TGFB1* did not reach significance (although
564 transcripts from all genes were detected).

565

566 **4 Discussion**

567

568 Since their delineation by Gabrilovich in 2007 (78), MDSCs have been reported in
569 multiple inflammatory diseases in addition to cancer (79). Recently, Hedge et al. described
570 significant heterogeneity among these immune suppressive cells in the myeloid compartment
571 (13). They stated that historically we have had a ‘*monolithic view*’ or definition of MDSCs, and
572 that a more complex ‘*emergent view*’ is required to better understand these leukocytes (13). In
573 this report, we have taken both conceptual approaches (monolithic and emergent) to analyze
574 MDSCs in one of the first cohorts to compare patients with poor (CCI) versus good (rapid
575 recovery) clinical outcomes after surgical sepsis. Importantly, all analyses revealed significant
576 alterations in the evolution of MDSCs after sepsis (i.e. time points) as well as significant
577 differences in the MDSC subpopulations taken from sepsis survivors who rapidly recovered or
578 developed CCI. In classifying MDSCs via gene expression and transcriptomic analysis, we have
579 also identified a novel MDSC subpopulation (H-MDSCs) present only in sepsis survivors with
580 CCI and acutely septic patients who progressed to CCI. Finally, even though we have
581 demonstrated in this work and previously (16) that these cells suppressed lymphocyte
582 proliferation to antigenic stimulation (similar to oncologic processes), the MDSCs identified
583 after sepsis do not significantly express many of the well-described genes key to MDSC
584 immunosuppression in other pathologies, most commonly cancer (80).

585 The study of MDSCs has expanded dramatically over the past decade. However, the
586 overwhelming majority of these studies performed using blood samples are from cancer patients;
587 only five studies focus on systemic infection and sepsis (8, 14, 81-83). Although MDSCs are
588 commonly detected in different inflammatory pathologies, there is a gap in research regarding
589 this cell type in the infected or post-infected host. Data are increasingly illustrating the impact of
590 a dysregulated myeloid compartment in patients with poor long-term outcomes, including
591 COVID-19 (84). MDSCs have been identified in these patients, especially those with more
592 severe disease or poor outcomes (85, 86), and are being considered as a target for
593 immunotherapy (87).

594 MDSCs are challenging to define and characterize. As such, cell surface markers and
595 genes historically used to identify MDSC subpopulations were amassed from multiple different
596 resources, predominantly from the cancer literature. Surface markers differ between humans and
597 other species, so only human studies could be considered (88, 89). Based on previous work, we
598 began by isolating CD66b⁺ PBMCs as a means to obtain PMN-MDSCs for functional analysis in
599 septic patients and healthy subjects (10). Interestingly, although we found that the purity of the
600 isolation of CD66b⁺ leukocytes (**Fig. S1**) was very good, and even though CD66b is considered a
601 marker for granulocytes (90), we identified that the CD66b⁺ population consisted of a mixture of
602 PMN- and M-MDSCs (**Fig. S2**). Although there can be populations of MDSCs that have
603 different levels of both CD14 or CD15 cell surface expression (91), these positively isolated
604 CD66b⁺ PBMCs were a combination of CD14⁺CD15⁻CD66b^{low} (M-MDSC) and
605 CD15⁺CD66b^{high} (PMN-MDSC) cells. Our CITE-seq data confirmed that *CEACAM8* expression
606 was present in multiple myeloid cell populations. This variable MDSC cell surface expression of
607 CD66b in septic patients appears similar to a cell type described in 1998 to define asynchronous
608 myelopoiesis in malignant myeloid disorders (92). This highlights some of the difficulty
609 regarding the use of cell surface phenotypes to classify MDSC subtypes after sepsis.

610 Of note, MDSCs are continuing to be described in certain patient populations, including
611 sepsis, through cell surface markers only (93, 94). Although these data may be valid, our analysis
612 would indicate that the traditional “*monolithic*” definition of MDSCs may not adequately define
613 these plastic, transitory cell populations in critically ill patients with sepsis. Our results do not
614 refute any currently accepted definitions of human MDSCs (including by cell marker phenotype)
615 (10), but rather illustrate the complexity of the myelodysplasia that occurs after human sepsis,
616 and the shortcomings of cell surface markers alone to identify myeloid cell types after severe
617 infection. In addition, other immunosuppressive cells exist in the PBMCs of whole blood from
618 septic human patients, specifically low-density PMNs and exhausted monocytes (95, 96). This
619 work, and our current results, indicate an immediate compelling need for more refined and
620 nuanced descriptions and definitions of the myeloid compartment after sepsis.

621 Veglia et al. previously described transcriptomic differences between MDSCs and
622 terminally differentiated monocytes and neutrophils (66). Additional guidelines for
623 characterization and nomenclature of MDSCs based on cell surface phenotypes have been
624 proposed, although the same central resource does not appear to exist for single-cell
625 transcriptomic signatures of different MDSC subpopulations (65, 97). However, specific genes
626 have been described in the literature. In cancer, *STAT3* is important for the T-cell suppression
627 exerted by MDSCs (98). *STAT1*, -5, and -6 are also important in the regulation of arginase
628 activity, although this may be more pertinent for cancer than sepsis based on the subdued level of
629 *ARG1* expression in MDSCs identified from our septic patients (**Fig. 10**) (98). It should also be
630 noted that different subpopulations than the canonical PMN- and M-MDSCs have been
631 previously described, including Eo-MDSCs (with eosinophilic characteristics) and fibrocystic
632 MDSCs (99, 100).

633 A population of H-MDSCs was found when using the “*emergent*” classification system
634 of MDSCs via genetic expression in order to classify cell types (**Fig. 5C**). All four MDSC
635 subpopulations appeared strongly interrelated and our data indicated that these cells are likely
636 plastic in their myeloid state after sepsis (**Fig. 6B**) (13). As to why we classified these cells as
637 unique from previously defined MDSC subpopulations, H-MDSCs express many similar genes
638 as PMN-MDSCs, although the average expression of these genes tends to be lower, such as with
639 *IL1R2*, *CST7* and *MMP8/9*. H-MDSCs also share substantial overlap with M-MDSCs, with
640 higher expression in sepsis of genes like *S100A8/9* and *DNAH17* (**Fig. 10**). H-MDSCs may be an
641 intermediary between MDSC subpopulations, and their presence in CCI further reveals the
642 plasticity of myeloid differentiation in sepsis (**Fig. 8**). Although MDSC subpopulations share a
643 similar phenotype after sepsis, their function and transcriptomic patterns are distinct. Thus, after
644 sepsis, ‘*a MDSC is not a MDSC*,’ and there is a unique expression of myelodysplasia after severe
645 infection depending on both host and outcome. These data support the concept that targeted
646 therapeutic strategies will be required within these sepsis phenotypes given the heterogenic
647 response of the myeloid compartment to sepsis.

648 This study was limited by the number of patients in each study arm; however, our sample
649 size estimates were similar to past publications in the field (14, 101). This is also a single-
650 institution study in which treatment of sepsis is standardized but may differ compared to other
651 institutions. Additionally, we did not stratify septic patients by septic source. Future directions
652 include stratification of our patient cohorts by infection source and demographic information
653 such as age, sex, and ethnicity/race to determine confounding factors which may have affected
654 our analysis by different clinical outcomes after sepsis.

655 In summary, we have determined that the post-septic myeloid compartment is complex
656 and includes a unique MDSC subpopulation that has not been previously described. Importantly,
657 the heterogeneous response of the blood myeloid compartment to sepsis varies based on time and
658 clinical outcome (CCI vs rapid recovery) and demonstrates that cell surface markers may not be
659 a reliable indicator of circulating myeloid cell types after sepsis. Sepsis, like many other
660 pathologies, requires a precision/personalized medical approach in order to improve host
661 outcomes (22). Our work reveals specific cell types and pathways that could be modified in
662 patients at risk of poor outcomes after sepsis (CCI) to convert them to a phenotype of rapid
663 recovery.
664

665 **5 References**

- 666 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al.,
667 The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*.
668 **315**, 801-10 (2016).
- 669 2. Stortz JA, Mira JC, Raymond SL, Loftus TJ, Ozrazgat-Baslanti T, Wang Z, et al.,
670 Benchmarking clinical outcomes and the immunocatabolic phenotype of chronic critical illness
671 after sepsis in surgical intensive care unit patients. *J Trauma Acute Care Surg*. **84**, 342-9 (2018).
- 672 3. Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, et al.,
673 A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. *Mol Med*. **17**, 281-
674 92 (2011).
- 675 4. Mathias B, Delmas AL, Ozrazgat-Baslanti T, Vanzant EL, Szpila BE, Mohr AM, et al.,
676 Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression
677 After Severe Sepsis/Septic Shock. *Ann Surg*. **265**, 827-34 (2017).
- 678 5. Horiguchi H, Loftus TJ, Hawkins RB, Raymond SL, Stortz JA, Hollen MK, et al., Innate
679 Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its
680 Implications for Therapy. *Front Immunol*. **9**, 595 (2018).
- 681 6. Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, et al., Interferon-
682 gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via
683 nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. *Blood*. **116**, 1124-31
684 (2010).
- 685 7. Kondo Y, Tachikawa E, Ohtake S, Kudo K, Mizuma K, Kashimoto T, et al.,
686 Inflammatory cytokines decrease the expression of nicotinic acetylcholine receptor during the
687 cell maturation. *Mol Cell Biochem*. **333**, 57-64 (2010).
- 688 8. Uhel F, Azzaoui I, Gregoire M, Pangault C, Dulong J, Tadie JM, et al., Early Expansion
689 of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of
690 Nosocomial Infections in Patients with Sepsis. *Am J Respir Crit Care Med*. **196**, 315-27 (2017).
- 691 9. Coudereau R, Waeckel L, Cour M, Rimmelé T, Pescarmona R, Fabri A, et al.,
692 Emergence of immunosuppressive LOX-1+ PMN-MDSC in septic shock and severe COVID-19
693 patients with acute respiratory distress syndrome. *Journal of leukocyte biology*. **111**, 489-96
694 (2022).
- 695 10. Veglia F, Sanseviero E, Gabrilovich DI, Myeloid-derived suppressor cells in the era of
696 increasing myeloid cell diversity. *Nat Rev Immunol*. **21**, 485-98 (2021).
- 697 11. Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, et al.,
698 Recommendations for myeloid-derived suppressor cell nomenclature and characterization
699 standards. *Nat Commun*. **7**, 12150 (2016).
- 700 12. Mira JC, Cuschieri J, Ozrazgat-Baslanti T, Wang Z, Ghita GL, Loftus TJ, et al., The
701 Epidemiology of Chronic Critical Illness After Severe Traumatic Injury at Two Level-One
702 Trauma Centers. *Crit Care Med*. **45**, 1989-96 (2017).
- 703 13. Hegde S, Leader AM, Merad M, MDSC: Markers, development, states, and unaddressed
704 complexity. *Immunity*. **54**, 875-84 (2021).
- 705 14. Darden DB, Bacher R, Brusko MA, Knight P, Hawkins RB, Cox MC, et al., Single-Cell
706 RNA-seq of Human Myeloid-Derived Suppressor Cells in Late Sepsis Reveals Multiple Subsets
707 With Unique Transcriptional Responses: A Pilot Study. *Shock (Augusta, Ga)*. **55**, 587-95 (2021).
- 708 15. Loftus TJ, Mira JC, Ozrazgat-Baslanti T, Ghita GL, Wang Z, Stortz JA, et al., Sepsis and
709 Critical Illness Research Center investigators: protocols and standard operating procedures for a

- 710 prospective cohort study of sepsis in critically ill surgical patients. *BMJ Open*. **7**, e015136
711 (2017).
- 712 16. Hollen MK, Stortz JA, Darden D, Dirain ML, Nacionales DC, Hawkins RB, et al.,
713 Myeloid-derived suppressor cell function and epigenetic expression evolves over time after
714 surgical sepsis. *Crit Care*. **23**, 355 (2019).
- 715 17. Brakenridge SC, Efron PA, Cox MC, Stortz JA, Hawkins RB, Ghita G, et al., Current
716 Epidemiology of Surgical Sepsis: Discordance Between Inpatient Mortality and 1-year
717 Outcomes. *Ann Surg*. **270**, 502-10 (2019).
- 718 18. Darden DB, Brakenridge SC, Efron PA, Ghita GL, Fenner BP, Kelly LS, et al.,
719 Biomarker Evidence of the Persistent Inflammation, Immunosuppression and Catabolism
720 Syndrome (PICS) in Chronic Critical Illness (CCI) After Surgical Sepsis. *Ann Surg*. **274**, 664-73
721 (2021).
- 722 19. Trellakis S, Bruderek K, Hutte J, Elian M, Hoffmann TK, Lang S, et al., Granulocytic
723 myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with
724 serum concentrations of colony-stimulating factors in head and neck cancer. *Innate Immun*. **19**,
725 328-36 (2013).
- 726 20. Blanter M, Gouwy M, Struyf S, Studying Neutrophil Function in vitro: Cell Models and
727 Environmental Factors. *J Inflamm Res*. **14**, 141-62 (2021).
- 728 21. Schenz J, Obermaier M, Uhle S, Weigand MA, Uhle F, Low-Density Granulocyte
729 Contamination From Peripheral Blood Mononuclear Cells of Patients With Sepsis and How to
730 Remove It - A Technical Report. *Front Immunol*. **12**, 684119 (2021).
- 731 22. Darden DB, Kelly LS, Fenner BP, Moldawer LL, Mohr AM, Efron PA, Dysregulated
732 Immunity and Immunotherapy after Sepsis. *J Clin Med*. **10**, (2021).
- 733 23. Zheng GX, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al., Massively
734 parallel digital transcriptional profiling of single cells. *Nat Commun*. **8**, 14049 (2017).
- 735 24. Andrews S. A quality control tool for high throughput sequence data: Babraham
736 Bioinformatics; 2010 [Available from:
737 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>].
- 738 25. Gaidatzis D, Burger L, Florescu M, Stadler MB, Analysis of intronic and exonic reads in
739 RNA-seq data characterizes transcriptional and post-transcriptional regulation. *Nat Biotechnol*.
740 **33**, 722-9 (2015).
- 741 26. Srivastava A, Malik L, Sarkar H, Patro R, A Bayesian framework for inter-cellular
742 information sharing improves dscRNA-seq quantification. *Bioinformatics*. **36**, i292-i9 (2020).
- 743 27. Srivastava A, Malik L, Smith T, Sudbery I, Patro R, Alevin efficiently estimates accurate
744 gene abundances from dscRNA-seq data. *Genome Biol*. **20**, 65 (2019).
- 745 28. He D, Zakeri M, Sarkar H, Sonesson C, Srivastava A, Patro R, Alevin-fry unlocks rapid,
746 accurate and memory-frugal quantification of single-cell RNA-seq data. *Nat Methods*. **19**, 316-
747 22 (2022).
- 748 29. R: A language and environment for statistical computing.: The R Foundation; 2022
749 [Available from: <https://www.r-project.org/>].
- 750 30. Python Language Reference: Python; 2019 [Available from: <https://docs.python.org/3/>].
- 751 31. Zhu A, Srivastava A, Ibrahim JG, Patro R, Love MI, Nonparametric expression analysis
752 using inferential replicate counts. *Nucleic Acids Res*. **47**, e105 (2019).
- 753 32. Griffiths JA, Richard AC, Bach K, Lun ATL, Marioni JC, Detection and removal of
754 barcode swapping in single-cell RNA-seq data. *Nat Commun*. **9**, 2667 (2018).

- 755 33. Lun ATL, Riesenfeld S, Andrews T, Dao TP, Gomes T, participants in the 1st Human
756 Cell Atlas J, et al., EmptyDrops: distinguishing cells from empty droplets in droplet-based
757 single-cell RNA sequencing data. *Genome Biol.* **20**, 63 (2019).
- 758 34. Hao Y, Hao S, Andersen-Nissen E, Mauck WM, 3rd, Zheng S, Butler A, et al., Integrated
759 analysis of multimodal single-cell data. *Cell.* **184**, 3573-87 e29 (2021).
- 760 35. Tirosh I, Izar B, Prakadan SM, Wadsworth MH, 2nd, Treacy D, Trombetta JJ, et al.,
761 Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science.*
762 **352**, 189-96 (2016).
- 763 36. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al., Fast, sensitive
764 and accurate integration of single-cell data with Harmony. *Nat Methods.* **16**, 1289-96 (2019).
- 765 37. McInnes LH, J.; Melville, J. . UMAP: Uniform Manifold Approximation and Projection
766 for Dimension Reduction Cornell University2018 [Available from:
767 <https://arxiv.org/abs/1802.03426>.
- 768 38. Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E, Fast unfolding of communities in
769 large networks. *Journal of Statistical Mechanics: Theory and Experiment.* **2008**, P10008 (2008).
- 770 39. Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al., Reference-based analysis of
771 lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol.* **20**, 163-
772 72 (2019).
- 773 40. Schmiedel BJ, Singh D, Madrigal A, Valdovino-Gonzalez AG, White BM, Zapardiel-
774 Gonzalo J, et al., Impact of Genetic Polymorphisms on Human Immune Cell Gene Expression.
775 *Cell.* **175**, 1701-15 e16 (2018).
- 776 41. Martens JH, Stunnenberg HG, BLUEPRINT: mapping human blood cell epigenomes.
777 *Haematologica.* **98**, 1487-9 (2013).
- 778 42. Consortium EP, An integrated encyclopedia of DNA elements in the human genome.
779 *Nature.* **489**, 57-74 (2012).
- 780 43. Mabbott NA, Baillie JK, Brown H, Freeman TC, Hume DA, An expression atlas of
781 human primary cells: inference of gene function from coexpression networks. *BMC Genomics.*
782 **14**, 632 (2013).
- 783 44. Monaco G, Lee B, Xu W, Mustafah S, Hwang YY, Carre C, et al., RNA-Seq Signatures
784 Normalized by mRNA Abundance Allow Absolute Deconvolution of Human Immune Cell
785 Types. *Cell Rep.* **26**, 1627-40 e7 (2019).
- 786 45. Bauer DF, Constructing Confidence Sets Using Rank Statistics. *Journal of the American*
787 *Statistical Association.* **67**, 687-90 (1972).
- 788 46. Miller RG. Simultaneous Statistical Inference. Second ed: Springer International
789 Publishing; 2012. 315 p.
- 790 47. Crowell HL, Soneson C, Germain PL, Calini D, Collin L, Raposo C, et al., muscat
791 detects subpopulation-specific state transitions from multi-sample multi-condition single-cell
792 transcriptomics data. *Nat Commun.* **11**, 6077 (2020).
- 793 48. Benzanson JE, A; Karpinski, S; Shah, VB, Julia: A Fresh Approach to Numerical
794 Computing. *SIAM Rev.* **59**, 65-98 (2017).
- 795 49. Bates DA, P; Kleinschmidt, D; Calderon, JBS; Noack, A; Kelman, T; Bouchet-Valat, M;
796 Gagnon, YL; Babayan, S; Mogensen, PK; Piibeleht, M; Hatherly, M; Saba, E; Baldassari, A.
797 JuliaStats/MixedModels.jl: v2.3.0 (v.2.3.0): Zenodo; 2020 [Available from:
798 <https://doi.org/10.5281/zenodo.3727845>.
- 799 50. Holm S, A simple sequentially rejective multiple test procedure. *Scand J Stat.* **6**, 65-70
800 (1979).

- 801 51. Kolberg L, Raudvere U, Kuzmin I, Vilo J, Peterson H, gprofiler2 -- an R package for
802 gene list functional enrichment analysis and namespace conversion toolset g:Profiler. *F1000Res.*
803 **9**, (2020).
- 804 52. Bhuva DD. vissE: Visualising Set Enrichment Analysis Results 2022 [Available from:
805 <https://davislaboratory.github.io/vissE>].
- 806 53. Melville J. uwot: The Uniform Manifold Approximation and Projection (UMAP) method
807 for dimensionality reduction. 2022 [Available from: <https://CRAN.R-project.org/package=uwot>].
- 808 54. Virshup I, Rybakov S, Theis FJ, Angerer P, Wolf FA, anndata: Annotated data. *bioRxiv.*
809 2021.12.16.473007 (2021).
- 810 55. La Manno G, Soldatov R, Zeisel A, Braun E, Hochgerner H, Petukhov V, et al., RNA
811 velocity of single cells. *Nature.* **560**, 494-8 (2018).
- 812 56. Bergen V, Lange M, Peidli S, Wolf FA, Theis FJ, Generalizing RNA velocity to transient
813 cell states through dynamical modeling. *Nat Biotechnol.* **38**, 1408-14 (2020).
- 814 57. Lange M, Bergen V, Klein M, Setty M, Reuter B, Bakhti M, et al., CellRank for directed
815 single-cell fate mapping. *Nat Methods.* **19**, 159-70 (2022).
- 816 58. Wolf FA, Hamey FK, Plass M, Solana J, Dahlin JS, Gottgens B, et al., PAGA: graph
817 abstraction reconciles clustering with trajectory inference through a topology preserving map of
818 single cells. *Genome Biol.* **20**, 59 (2019).
- 819 59. Wolf FA, Angerer P, Theis FJ, SCANPY: large-scale single-cell gene expression data
820 analysis. *Genome Biol.* **19**, 15 (2018).
- 821 60. Jacomy M, Venturini T, Heymann S, Bastian M, ForceAtlas2, a continuous graph layout
822 algorithm for handy network visualization designed for the Gephi software. *PLoS One.* **9**, e98679
823 (2014).
- 824 61. Fruchterman TMJ, Reingold EM, Graph drawing by force-directed placement. *Software:*
825 *Practice and Experience.* **21**, 1129-64 (1991).
- 826 62. Pinheiro JCBDMRCT. nlme: Linear and Nonlinear Mixed Effects Models 2023
827 [Available from: <https://CRAN.R-project.org/package=nlme>].
- 828 63. Lenth RVBBB, P.; Gine-Vazquez, I.; Herve, M.; Jung, M.; Love, J.; Miguez, F.; Riebl,
829 H. and Singmann, H. emmeans: Estimated Marginal Means, aka Least-Squares Means 2023
830 [Available from: <https://CRAN.R-project.org/package=emmeans>].
- 831 64. Stoeckius M, Hafemeister C, Stephenson W, Houck-Loomis B, Chattopadhyay PK,
832 Swerdlow H, et al., Simultaneous epitope and transcriptome measurement in single cells. *Nat*
833 *Methods.* **14**, 865-8 (2017).
- 834 65. Bronte V, Brandau S, Chen S-H, Colombo MP, Frey AB, Greten TF, et al.,
835 Recommendations for myeloid-derived suppressor cell nomenclature and characterization
836 standards. *Nature Communications.* **7**, (2016).
- 837 66. Veglia F, Sanseviero E, Gabrilovich DI, Myeloid-derived suppressor cells in the era of
838 increasing myeloid cell diversity. *Nature Reviews Immunology.* **21**, 485 - 98 (2021).
- 839 67. Gabrilovich DI, Myeloid-Derived Suppressor Cells. *Cancer Immunol Res.* **5**, 3-8 (2017).
- 840 68. Luperto M, Zafrani L, T cell dysregulation in inflammatory diseases in ICU. *Intensive*
841 *Care Med Exp.* **10**, 43 (2022).
- 842 69. Pray BA, Youssef Y, Alinari L, TBL1X: At the crossroads of transcriptional and
843 posttranscriptional regulation. *Exp Hematol.* **116**, 18-25 (2022).
- 844 70. Itskovich SS, Gurunathan A, Clark J, Burwinkel M, Wunderlich M, Berger MR, et al.,
845 MBNL1 regulates essential alternative RNA splicing patterns in MLL-rearranged leukemia. *Nat*
846 *Commun.* **11**, 2369 (2020).

- 847 71. Zhang Q, Wu Y, Chen J, Tan F, Mou J, Du Z, et al., The Regulatory Role of Both
848 MBNL1 and MBNL1-AS1 in Several Common Cancers. *Curr Pharm Des.* **28**, 581-5 (2022).
- 849 72. Li X, Li Y, Yu Q, Qian P, Huang H, Lin Y, Metabolic reprogramming of myeloid-
850 derived suppressor cells: An innovative approach confronting challenges. *J Leukoc Biol.* **110**,
851 257-70 (2021).
- 852 73. Santos SS, Carmo AM, Brunialti MK, Machado FR, Azevedo LC, Assuncao M, et al.,
853 Modulation of monocytes in septic patients: preserved phagocytic activity, increased ROS and
854 NO generation, and decreased production of inflammatory cytokines. *Intensive Care Med Exp.* **4**,
855 5 (2016).
- 856 74. Gong FC, Ji R, Wang YM, Yang ZT, Chen Y, Mao EQ, et al., Identification of Potential
857 Biomarkers and Immune Features of Sepsis Using Bioinformatics Analysis. *Mediators Inflamm.*
858 **2020**, 3432587 (2020).
- 859 75. Wu W, Zhang X, Lv H, Liao Y, Zhang W, Cheng H, et al., Identification of immediate
860 early response protein 2 as a regulator of angiogenesis through the modulation of endothelial cell
861 motility and adhesion. *Int J Mol Med.* **36**, 1104-10 (2015).
- 862 76. Kyjacova L, Saup R, Ronsch K, Wallbaum S, Dukowic-Schulze S, Foss A, et al., IER2-
863 induced senescence drives melanoma invasion through osteopontin. *Oncogene.* **40**, 6494-512
864 (2021).
- 865 77. Chung TP, Laramie JM, Meyer DJ, Downey T, Tam LH, Ding H, et al., Molecular
866 diagnostics in sepsis: from bedside to bench. *J Am Coll Surg.* **203**, 585-98 (2006).
- 867 78. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, et
868 al., The terminology issue for myeloid-derived suppressor cells. *Cancer Res.* **67**, 425; author
869 reply 6 (2007).
- 870 79. Veglia F, Perego M, Gabrilovich D, Myeloid-derived suppressor cells coming of age. *Nat*
871 *Immunol.* **19**, 108-19 (2018).
- 872 80. Li K, Shi H, Zhang B, Ou X, Ma Q, Chen Y, et al., Myeloid-derived suppressor cells as
873 immunosuppressive regulators and therapeutic targets in cancer. *Signal Transduct Target Ther.*
874 **6**, 362 (2021).
- 875 81. Kotze LA, van der Spuy G, Leonard B, Penn-Nicholson A, Musvosvi M, McAnda S, et
876 al., Targeted Gene Expression Profiling of Human Myeloid Cells From Blood and Lung
877 Compartments of Patients With Tuberculosis and Other Lung Diseases. *Front Immunol.* **13**,
878 839747 (2022).
- 879 82. Dean MJ, Ochoa JB, Sanchez-Pino MD, Zabaleta J, Garai J, Del Valle L, et al., Severe
880 COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of
881 Arginase Producing Granulocytic Myeloid Derived Suppressor Cells. *Front Immunol.* **12**,
882 695972 (2021).
- 883 83. Chen L, Jin S, Yang M, Gui C, Yuan Y, Dong G, et al., Integrated Single Cell and Bulk
884 RNA-Seq Analysis Revealed Immunomodulatory Effects of Ulinastatin in Sepsis: A Multicenter
885 Cohort Study. *Front Immunol.* **13**, 882774 (2022).
- 886 84. Schulte-Schrepping J, Reusch N, Paclik D, Bassler K, Schlickeiser S, Zhang B, et al.,
887 Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment. *Cell.* **182**, 1419-40
888 e23 (2020).
- 889 85. Kiaee F, Jamaati H, Shahi H, Roofchayee ND, Varahram M, Folkerts G, et al.,
890 Immunophenotype and function of circulating myeloid derived suppressor cells in COVID-19
891 patients. *Sci Rep.* **12**, 22570 (2022).

- 892 86. Xu G, Qi F, Li H, Yang Q, Wang H, Wang X, et al., The differential immune responses
893 to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing. *Cell Discov.* **6**, 73
894 (2020).
- 895 87. Rowlands M, Segal F, Hartl D, Myeloid-Derived Suppressor Cells as a Potential
896 Biomarker and Therapeutic Target in COVID-19. *Front Immunol.* **12**, 697405 (2021).
- 897 88. Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, et al., Transcriptomic
898 analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor
899 cells and normal neutrophils. *PLoS One.* **7**, e31524 (2012).
- 900 89. Millrud CR, Bergenfelz C, Leandersson K, On the origin of myeloid-derived suppressor
901 cells. *Oncotarget.* **8**, 3649-65 (2017).
- 902 90. McKenna E, Mhaonaigh AU, Wubben R, Dwivedi A, Hurley T, Kelly LA, et al.,
903 Neutrophils: Need for Standardized Nomenclature. *Front Immunol.* **12**, 602963 (2021).
- 904 91. Vetsika EK, Koinis F, Gioulbasani M, Aggouraki D, Koutoulaki A, Skalidaki E, et al., A
905 circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent
906 prognostic/predictive factor in untreated non-small lung cancer patients. *J Immunol Res.* **2014**,
907 659294 (2014).
- 908 92. Hansen I, Meyer K, Hokland P, Flow cytometric identification of myeloid disorders by
909 asynchronous expression of the CD14 and CD66 antigens. *European journal of haematology.* **61**,
910 339-46 (1998).
- 911 93. Feng S, Cui Y, Zhou Y, Shao L, Miao H, Dou J, et al., Continuous renal replacement
912 therapy attenuates polymorphonuclear myeloid-derived suppressor cell expansion in pediatric
913 severe sepsis. *Front Immunol.* **13**, 990522 (2022).
- 914 94. De Zuani M, Hortova-Kohoutkova M, Andrejcinova I, Tomaskova V, Sramek V, Helan
915 M, et al., Human myeloid-derived suppressor cell expansion during sepsis is revealed by
916 unsupervised clustering of flow cytometric data. *Eur J Immunol.* **51**, 1785-91 (2021).
- 917 95. Sun R, Huang J, Yang Y, Liu L, Shao Y, Li L, et al., Dysfunction of low-density
918 neutrophils in peripheral circulation in patients with sepsis. *Sci Rep.* **12**, 685 (2022).
- 919 96. Pradhan K, Yi Z, Geng S, Li L, Development of Exhausted Memory Monocytes and
920 Underlying Mechanisms. *Front Immunol.* **12**, 778830 (2021).
- 921 97. Bergenfelz C, Leandersson K, The Generation and Identity of Human Myeloid-Derived
922 Suppressor Cells. *Front Oncol.* **10**, 109 (2020).
- 923 98. Condamine T, Gabrilovich DI, Molecular mechanisms regulating myeloid-derived
924 suppressor cell differentiation and function. *Trends Immunol.* **32**, 19-25 (2011).
- 925 99. Goldmann O, Beineke A, Medina E, Identification of a Novel Subset of Myeloid-Derived
926 Suppressor Cells During Chronic Staphylococcal Infection That Resembles Immature
927 Eosinophils. *The Journal of Infectious Diseases.* **216**, 1444-51 (2017).
- 928 100. Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, et al., Fibrocytes
929 represent a novel MDSC subset circulating in patients with metastatic cancer. *Blood.* **122**, 1105-
930 13 (2013).
- 931 101. Darden DB, Dong X, Brusko MA, Kelly L, Fenner B, Rincon JC, et al., A Novel Single
932 Cell RNA-seq Analysis of Non-Myeloid Circulating Cells in Late Sepsis. *Front Immunol.* **12**,
933 696536 (2021).
- 934

935 6 Figure Legends

936

937 **Figure 1. Single-cell analysis of myeloid cells using surface protein makers.** (A) Illustration
938 representing the historical/classic/monolithic definition of MDSCs. E-, PMN-, and M-MDSCs
939 are the predominant subpopulations with distinct phenotypes and functions (modified from
940 Hegde et al. (13)). (B) Cell proportions of monocyte subtypes and MDSCs relative to overall
941 monocytic cells are shown for healthy subjects (“Healthy”) (n=12), septic patients 4 days
942 following diagnosis (“Day 4 ± 1”) (n=4), and septic patients at days 14-21 (separated into those
943 experiencing chronic critical illness (“CCI”) (n=5) or those who rapidly recovered (“RAP”)
944 (n=4)). (C) UMAP embedding of single-cell transcriptomes of peripheral blood mononuclear
945 cells (PBMCs). Cells are colored by the timepoint at which the samples were taken. Samples
946 from day 4 and days 14-21 are from septic patients. (D) Similar to (C), with cells colored by cell
947 type. M: monocytic, PMN: granulocytic, E: early.

948

949 **Figure 2. Analysis via CITE-seq of differential gene expression of PMN- and M-MDSC**
950 **subpopulations at different time points relative to healthy subjects.** (A) Within PMN-
951 MDSCs, gene expression of twelve healthy subjects (baseline) was compared with septic patients
952 at day 4 (“Day 4 ± 1”) (n=4) and septic patients at days 14-21 (subdivided into chronic critical
953 illness (“CCI”) (n=5) and rapid recovery (“RAP”) (n=4)). Differential expression results relative
954 to healthy subjects were compared for each pair of septic time points (left panel: day 4 vs CCI,
955 middle panel: day 4 vs RAP, right panel: RAP vs CCI). The x-axis is the absolute difference in
956 the *p*-value per gene ($|\Delta p\text{-value}|$) and the y-axis is the difference in log fold-change ($\Delta \log\text{FC}$).
957 The colored points represent genes that were differentially expressed in a single group or for
958 both groups (*p*-value < 0.01). (B) Venn diagram of genes with overlapping significant
959 differential expression (*p*-value < 0.01). (C) Enrichment results of significant genes representing
960 the gene ontology biological processes. The y-axis is the negative log (base 10) of the *p*-value ($-\log_{10}(p\text{value})$). (D-F) Similar to (A-C) for M-MDSCs. PMN: granulocytic, M: monocytic.

961

962 **Figure 3. UMAP embeddings of peripheral blood mononuclear cells (PBMCs).** (A) Cells are
963 colored by the time point at which the samples were taken. Samples from acutely septic patients
964 (“Day 4±1”) and late sepsis patients who either developed chronic critical illness (“CCI”) or
965 experienced rapid recovery (“RAP”). (B) Cells are colored by septic cohort. Late sepsis patients
966 at day 14-21 are separated into two groups denoted “CCI” (chronic critical illness) and “RAP”
967 (rapid recovery) based on their response to the sepsis. (C) Expression of surface markers on
968 subtypes of PBMCs. (D) The left panel denotes percentages of spliced mRNA in different cell
969 types separated by patient cohort. The right panel denotes overall unspliced mRNA across cell
970 types by patient cohort. B: B cells, NK: natural killer cells, HSPC: hematopoietic stem and
971 progenitor cells, pDC: plasmacytoid dendritic cells.

972

973 **Figure 4. Marker gene expression across myeloid cell types in septic patients.** A dot plot
974 shows scaled mean expression of the top seven most significant differentially expressed genes
975 (DEGs) in each myeloid cell type prior to fine-level annotation for MDSC subpopulations. Point
976 radius indicates the percentage of cells with nonzero expression, and color denotes relatively
977 higher or lower mean expression across cell types. Testing was performed with the Wilcox test,
978 and genes were ranked by adj. *p*-value after Bonferroni correction. CD14⁺: classical monocyte,
979

980 CD16⁺: non-classical monocyte, MK: megakaryocyte, cDC: conventional dendritic cells, infl.:
981 inflammatory, M: monocytic, E: early, PMN: granulocytic.

982
983 **Figure 5. “Emergent” view and annotation of myeloid cell subpopulations in septic**
984 **patients. (A)** Illustration representing the “emergent” definition of MDSCs, incorporating the
985 plasticity and heterogeneity of the myeloid compartment (modified from Hegde, et al (13)). **(B)**
986 Fine cell type annotations within cells from septic patients that were broadly annotated as
987 monocytes. The x-axis includes the different myeloid cell subtypes. The y-axis includes genes
988 which were most highly expressed by each cell subtype. The scaled mean expression is denoted
989 by the color of the dots, and the percentages of cells expressing the genes are represented by the
990 size of the dots. **(C)** UMAP plots of cells of the four distinct subpopulations of MDSCs stratified
991 by acutely septic patients (“Day 4±1”) (n=4), late sepsis patients who developed chronic critical
992 illness (“CCI”) (n=5) or experienced rapid recovery (“RAP”) (n=4). This includes cells
993 consistent with early (E-) MDSCs, granulocytic (PMN-) MDSCs, monocytic (M-) MDSCs, and a
994 population of cells with characteristics of both M- and PMN-MDSCs, labeled hybrid (H-)
995 MDSCs. MK: megakaryocyte, cDC: conventional dendritic cell, infl.: inflammatory.

996
997 **Figure 6. Characterizing data-driven subpopulations of MDSCs. (A)** Relative frequencies of
998 MDSCs by subpopulation. Percent of cells defined by transcriptomic analysis and gene
999 expression, rather than cell surface markers. Grouped by acutely septic patients (“Day 4±1”) (n=4)
1000 and late sepsis patients who developed chronic critical illness (“CCI”) (n=5) or
1001 experienced rapid recovery (“RAP”) (n=4). **(B)** Diagram of significant marker genes for each
1002 MDSC subpopulation were determined in the pooled septic patients. **(C)** UMAP plots of all
1003 MDSCs are shown for the seven genes that were unique markers of gene expression in the H-
1004 MDSC subpopulation compared to all other MDSCs. Scaled expression represented by heat map
1005 of each gene. **(D)** Differential expression testing between septic groups in M-MDSCs revealed
1006 four genes that were significant. Y-axis is log (expression +1). Asterisks represent *p*-value
1007 cutoffs of 0.05 and 0.001, respectively, obtained from the mixed model analysis. M: monocytic,
1008 PMN: granulocytic, E: early, H: hybrid.

1009
1010 **Figure 7. Larger proportions of unspliced mRNA in E- and H- MDSCs. (A)** Distribution of
1011 unspliced mRNA percent across myeloid cell types. **(B-E)** Gene-set enrichment analysis of genes
1012 having high proportions of unspliced mRNA within each MDSC subpopulation. The left panel
1013 shows the gene-set network and clustering of significantly enriched biological processes. The
1014 right panels show word clouds for each biologically similar cluster (a general cluster of high-
1015 level biological processes was present for each cell-type and omitted). E: early, H: hybrid, M:
1016 monocytic, PMN: granulocytic, CD16⁺: non-classical monocyte, CD14⁺: classical monocyte,
1017 MK: megakaryocyte, cDC: conventional dendritic cell, infl.: inflammatory.

1018
1019 **Figure 8. Topology of myeloid differentiation and plasticity in septic patients. (A)** Myeloid
1020 cell smoothed RNA velocity estimates projected onto UMAP. Arrows represent differentiation
1021 potential. **(B)** Undirected partition-based graph abstraction (PAGA) of myeloid cell types. Line
1022 width/color between cell types denote relationship strength. Nodes colored by cell type. **(C)**
1023 Arrow directions represent differentiation potential. Arrow widths denote strength of
1024 connectivities between cell types. Arrow manually added indicating PMN-MDSC differentiation
1025 into granulocytes. **(D)** Cell state probabilities shown together for M-, PMN-, and E-MDSCs with

1026 all other cells in gray. **(E)** Similar to **(D)** with H-MDSCs in red. **(F)** H-MDSC cell fate
 1027 absorption probabilities. cDC: conventional dendritic cell, infl.: inflammatory, CD16⁺: non-
 1028 classical monocyte, CD14⁺: classical monocyte, M: monocytic, H: hybrid, PMN: granulocytic,
 1029 E: early.

1030
 1031 **Figure 9. Differences in PMN-, E-, and M-MDSCs across septic time-points.** **(A)** Cell
 1032 dynamic parameters estimated from CellRank were compared across cells from septic patients at
 1033 Day 4±1 (acute sepsis) (n=4), patients at day 14-21 who rapidly recovered (“RAP”) (n=4), and
 1034 patients at day 14-21 who developed chronic critical illness (“CCI”) (n=5) in M-MDSCs. **(B-C)**
 1035 Similar to **(A)** for PMN-MDSCs and E-MDSCs, respectively. Significant p-values (< 0.05) were
 1036 obtained from fitting a linear mixed model. E: early, PMN: granulocytic, H: hybrid, M:
 1037 monocytic.

1038
 1039 **Figure 10. Canonical MDSC genes in immunosuppressive cell subpopulations in septic**
 1040 **patients.** Heatmap of scaled expression of canonical genes identified in the current MDSC
 1041 literature. Cells in the four identified MDSC subpopulations are denoted in the colored key.
 1042 Genes were arranged using hierarchical clustering with complete linkage. Patient groups include
 1043 acutely septic patients (“Day 4±1”) (n=4) and late sepsis patients who developed chronic critical
 1044 illness (“CCI”) (n=5) or experienced rapid recovery (“RAP”) (n=4). M: monocytic, PMN:
 1045 granulocytic, E: early, H: hybrid.

1046 7 Tables

1047
 1048
 1049 **Table 1. Patient characteristics between cohorts.** Cohorts are healthy control patients, acutely
 1050 septic patients, and late sepsis patients who experienced rapid recovery (RAP) and chronic
 1051 critical illness (CCI). BMI: body mass index, CCI: Charlson comorbidity index, COPD: chronic
 1052 obstructive pulmonary disease, DM: diabetes mellitus, HTN: hypertension, NSTI: necrotizing
 1053 soft tissue infection, SBO: small bowel obstruction, MCC: Motorcycle crash.

1054

	Healthy Subjects (n=12)	Sepsis Day 4 ± 1 (n=4)	RAP Days 14-21 (n=4)	CCI Days 14-21 (n=5)	p-value
Male, # (%)	7 (58)	1 (25)	1 (25)	3 (60)	0.48
Age in years, (μ ± SD)	46 ± 10	67 ± 22	61 ± 16	58 ± 18	0.08
BMI (μ ± SD)		39 ± 19	37 ± 20	21 ± 3	0.19
Septic shock, # (%)		4 (100)	1 (25)	4 (80)	
CCI (median)		5.5	2	2	
Comorbidities (#)	Cancer (1), COPD (1), DM (1), HTN (3)	COPD (1), DM (2), HTN (4)	COPD (1), DM (1), HTN (4)	DM (1), HTN (2)	
Admission Diagnosis (#)		NSTI (1), Cholelithiasis (1), SBO (1), Planned operation (1)	NSTI (2), SBO (2)	Planned operation (1), Complication (1), Intra-abdominal abscess (1), Pancreatitis (1), MCC (1)	

1055

1056 **Table 2. Percentage of Total MDSCs and MDSC subpopulations from PBMCs via flow**
 1057 **cytometry.** Percentages of total MDSC population in representative septic patients. Blood was
 1058 collected from healthy subjects (n=6), day 4 ± 1 septic patients (n=7), and late sepsis patients at
 1059 days 14-21 (n=3)). PBMCs were isolated and prepared for flow cytometry. Viable cells
 1060 determined followed by gating of CD11b⁺ and CD33⁺ cells. HLA-DR^{low} cells selected to capture
 1061 Total MDSCs. (CD11b⁺ CD33⁺ HLA-DR^{low}) Cells outside the gating of the three MDSC
 1062 subpopulations are classified as “% Ungated.”
 1063

MDSC Subpopulation	Healthy Subjects (n=6)	Sepsis Day 4 ± 1 (n=7)	Sepsis Days 14-21 (n=3)
% Total MDSCs	15.1 (8.1, 16.6)	39.2 (25.2, 55.6)	44.8 (35.6, 56.3)
% E-MDSC	68.1 (49.8, 78.7)	1.4 (0.7, 5.9)	2.3 (2.2, 9.0)
% PMN-MDSC	14.6 (7.4, 36.9)	79.5 (64.4, 89.0)	80.7 (52.0, 85.1)
% M-MDSC	9.2 (4.9, 12.7)	9.1 (8.1, 12.7)	11.5 (9.7, 35.9)
% Ungated	2.0 (1.4, 3.2)	0.7 (0.5, 1.3)	0.7 (0.7, 3.1)

1064
 1065 **Table 3. Percentage of Total MDSCs and MDSC subpopulations from PBMCs and**
 1066 **enriched myeloid cells via flow cytometry.** Percentages of total MDSC population in
 1067 representative septic patients. Peripheral blood mononuclear cells and myeloid cells were
 1068 collected from the same septic cohorts (n=3 for acute sepsis and n=6 for late sepsis patients) and
 1069 healthy subjects (n=9). A 3:1 mixture of myeloid cells: enriched PBMCs were prepared for flow
 1070 cytometry. Cells outside the gating of the three MDSC subpopulations are classified as “%
 1071 Ungated.” Results reported as median (Q1, Q3). E: early, PMN: granulocytic, M: monocytic.
 1072

MDSC Subpopulation	Healthy Subjects (n=9)	Sepsis Day 4±1 (n=3)	Sepsis Days 14-21 (n=6)
% Total MDSCs	0.3 (0.1, 0.3)	3.1 (1.8, 3.6)	0.8 (0.5, 1.3)
% E-MDSC	1.3 (1.1, 5.3)	0.7 (0.5, 1.2)	1.0 (0.5, 6.0)
% PMN-MDSC	22.9 (11.6, 30.3)	26.7 (16.5, 34.5)	23.5 (16.0, 39.9)
% M-MDSC	67.1 (64.6, 83.1)	71.0 (64.0, 81.4)	68.2 (57.2, 80.6)
% Ungated	0.3 (0.0, 0.5)	0.6 (0.3, 1.6)	0.5 (0.3, 0.7)

1073
 1074 **Table 4. H-MDSC cell counts by patient and associated outcome after sepsis.** H-MDSC cell
 1075 counts as determined by manual annotation. If blood samples were taken from acutely septic
 1076 patients at day 4, then their eventual sepsis classification has been recorded. H: hybrid, CCI:
 1077 chronic critical illness.
 1078

Patient #	Patient Classification	Eventual classification if acute sepsis	H-MDSC Cell Counts
1	Acute Sepsis	Early death	0
2	Acute Sepsis	Rapid recovery	0
3	Acute Sepsis	CCI	1

4	Acute Sepsis	CCI	8
5	Rapid recovery		0
6	Rapid recovery		0
7	Rapid recovery		0
8	Rapid recovery		0
9	CCI		552
10	CCI		6
11	CCI		1
12	CCI		0
13	CCI		0

1079

1080 **8 Conflict of Interest**

1081

1082 The authors declare that the research was conducted in the absence of any commercial or
1083 financial relationships that could be construed as a potential conflict of interest.

1084

1085 **9 Author Contributions**

1086

1087 Conceptualization: MK, CM, LLM, PAE

1088 Methodology: LLM, PAE

1089 Investigation: DBD, JCR, MW, MLD, RU, DCN, MLG, SL, LM, TL, AMM, RM, MK, CM,
1090 MAB, TMB, LLM, RB, PAE

1091 Visualization: LLM, PAE

1092 Funding acquisition: MK, CM, LLM, PAE

1093 Project administration: PAE

1094 Supervision: PAE

1095 Writing – original draft: ELB, JL, VP, LLM, RB, PAE

1096 Writing – review & editing: ELB, JL, DBD, JCR, MW, VP, GG, JM, MLD, RU, DCN, MLG,
1097 SL, LM, TL, AMM, RM, MK, CM, MAB, TMB, LLM, RB, PAE.

1098

1099 **10 Funding**

1100

1101 This work was supported, in part, by the following National Institutes of Health grants:

1102 National Institutes of Health grant RM1 GM139690 (LLM, PAE, MK, CM)

1103 National Institutes of Health grant R35 GM140806 (PAE)

1104 National Institute of General Medical Sciences grant R35 GM146895 (RB)

1105 National Institute of General Medical Sciences postgraduate training grant T32 GM-008721 (EB,
1106 DBD, VP, JM)

1107 National Institute of General Medical Sciences postgraduate training grant T32 HL160491 (GG)

1108

1109 **11 Acknowledgments**

1110

1111 The authors would like to thank LaShaun Bryant, BS, Brandi Buscemi, AS - Physical Therapist
1112 Assistant, Ruth Davis, BSN, Jennifer Lanz, MSN, RN, Ashley McCray, ASN, and Ivanna Rocha,
1113 MPH for their critical role with patient recruitment, retention and data collection as well as
1114 collection of human samples.

1115



1116 **12 Data availability**

1117

1118 The datasets generated for this study can be found in the Gene Expression Omnibus (in-process).


1119 All analysis codes are available upon request.

A Differentiation of Myeloid Cells - Classical Pathway




C







● Healthy ● Day 4±1 ● Day 14-21 (CCI) ● Day 14-21 (RAP)








D

● CD14+ Monocyte ● E-MDSC ● PMN-MDSC ● M-MDSC
● CD16+ Monocyte






A**B****C****D**




A


Differentiation of Myeloid Cells - Emergent Pathway







B




C







A




B



C



D



E

